Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease
Hironi Makita, Yasuyuki Nasuhara, Katsura Nagai, Yoko Ito, Masaru Hasegawa, Tomoko Betsuyaku, Yuya Onodera, Nobuyuki Hizawa, Masaharu Nishimura, Hokkaido COPD Cohort Study Group, Hironi Makita, Yasuyuki Nasuhara, Katsura Nagai, Yoko Ito, Masaru Hasegawa, Tomoko Betsuyaku, Yuya Onodera, Nobuyuki Hizawa, Masaharu Nishimura, Hokkaido COPD Cohort Study Group
Abstract
Background: Airflow limitation in chronic obstructive pulmonary disease (COPD) is caused by a mixture of small airway disease and emphysema, the relative contributions of which may vary among patients. Phenotypes of COPD classified purely based on severity of emphysema are not well defined and may be different from the classic phenotypes of "pink puffers" and "blue bloaters".
Methods: To characterise clinical phenotypes based on severity of emphysema, 274 subjects with COPD were recruited, excluding those with physician-diagnosed bronchial asthma. For all subjects a detailed interview of disease history and symptoms, quality of life (QOL) measurement, blood sampling, pulmonary function tests before and after inhalation of salbutamol (0.4 mg) and high-resolution CT scanning were performed.
Results: Severity of emphysema visually evaluated varied widely even among subjects with the same stage of disease. No significant differences were noted among three groups of subjects classified by severity of emphysema in age, smoking history, chronic bronchitis symptoms, blood eosinophil count, serum IgE level or bronchodilator response. However, subjects with severe emphysema had significantly lower body mass index (BMI) and poorer QOL scores, evaluated using St George's Respiratory Questionnaire (SGRQ), than those with no/mild emphysema (mean (SD) BMI 21.2 (0.5) vs 23.5 (0.3) kg/m(2), respectively; SGRQ total score 40 (3) vs 28 (2), respectively; p<0.001 for both). These characteristics held true even if subjects with the same degree of airflow limitation were chosen.
Conclusions: The severity of emphysema varies widely even in patients with the same stage of COPD, and chronic bronchitis symptoms are equally distributed irrespective of emphysema severity. Patients with the phenotype in which emphysema predominates have lower BMI and poorer health-related QOL.
Conflict of interest statement
Competing interests: None.
Figures
References
- Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2003). Bethesda, MD: National Heart, Lung and Blood Institute, World Health Organization 2003
- Fukuchi Y, Nishimura M, Ichinose al COPD in Japan: the Nippon COPD Epidemiology Study. Respirology 20049458–465.
- Lopez A D, Murray C C. The global burden of disease, 1990–2020. Nat Med 199841241–1243.
- Celli B R, MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 200423932–946.
- American Thoracic Society/European Respiratory Society Standards for the diagnosis and management of subjects with COPD. 2004. (accessed 2 September 2007)
- Hogg J C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004364709–721.
- Filley G F, Beckwitt H J, Reeves J al Chronic obstructive bronchopulmonary disease. II. Oxygen transport in two clinical types. Am J Med 19684426–38.
- Netter F, Divertie M, Brass A.The CIBA collection of medical illustrations: Volume 7: Respiratory systems. CIBA Pharmaceutical Company 1979
- Burrows B, Fletcher C M, Heard B al The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet 19661830–835.
- American Thoracic Society Standards for the diagnosis and care of subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995152S77–121.
- Hogg J C, Macklem P T, Thurlbeck W M. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 19682781355–1360.
- Yanai M, Sekizawa K, Ohrui al Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol 1992721016–1023.
- Wright J L, Lawson L M, Pare P al The detection of small airways disease. Am Rev Respir Dis 1984129989–994.
- Thurlbeck W M. The pathology of small airways in chronic airflow limitation. Eur J Respir Dis 1982121(Suppl)9–18.
- Hogg J C, Chu F, Utokaparch al The nature of small‐airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 20043502645–2653.
- Ciba Guest Symposium Report Terminology, definitions, and classification of chronic pulmonary emphysema and related condition. Thorax 196414286–299.
- Braman S S. Chronic cough due to chronic bronchitis: ACCP evidence‐based clinical practice guidelines. Chest 2006129104–15S.
- Committee of Pulmonary Physiology, the Japanese Respiratory Society Guidelines for pulmonary function tests: spirometry, flow‐volume curve, diffusion capacity of the lung (in Japanese). Tokyo: Japanese Respiratory Society 2004
- Goddard P R, Nicholson E M, Laszlo al Computed tomography in pulmonary emphysema. Clin Radiol 198233379–387.
- Jones P W, Quirk F H, Baveystock C al A self‐complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Am Rev Respir Dis 19921451321–1327.
- Gelb A F, Hogg J C, Muller N al Contribution of emphysema and small airways in COPD. Chest 1996109353–359.
- Hogg J C, Wright J L, Wiggs B al Lung structure and function in cigarette smokers. Thorax 199449473–478.
- Gelb A F, Schein M, Kuei al Limited contribution of emphysema in advanced chronic obstructive pulmonary disease. Am Rev Respir Dis 19931471157–1161.
- Celli B R, Cote C G, Marin J al The body‐mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 20043501005–1012.
- Anthonisen N R. Prognosis in chronic obstructive pulmonary disease: results from multicenter clinical trials. Am Rev Respir Dis 1989140S95–S99.
- Nishimura K, Izumi T, Tsukino al Dyspnea is a better predictor of 5‐year survival than airway obstruction in patients with COPD. Chest 20021211434–1440.
- Domingo‐Salvany A, Lamarca R, Ferrer al Hearth‐related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002166680–685.
- Marti S, Munoz X, Rios al Body weight and comorbidity predict mortality in COPD patients treated with oxygen therapy. Eur Respir J 200627689–696.
- Yoshioka A, Betsuyaku T, Nishimura al Excessive neutrophil elastase in bronchoalveolar lavage fluid in subclinical emphysema. Am J Respir Crit Care Med 19951522127–2132.
- Betsuyaku T, Nishimura M, Takeyabu al Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med 19991591985–1991.
- Takabatake N, Sata M, Inoue al A novel polymorphism in secretory phospholipase A2‐IID is associated with body weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 20051721097–1104.
- Japanese Respiratory Society COPD guideline for diagnosis and treatment (in Japanese). Tokyo: Japanese Respiratory Society 2004
- Anthonisen N R, Wright E C, the IPPB Trial Group Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986133814–819.
- Calverley P M, Burge P S, Spencer al Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 200358659–664.
- Anthonisen N R, Lindgren P G, Tashkin D al Lung Health Study Research Group. Bronchodilator response in the lung health study over 11 yrs. Eur Respir J 20052645–51.
- Gould G A, Redpath A T, Ryan al Lung CT density correlates with measurements of airflow limitation and the diffusing capacity. Eur Respir J 19914141–146.
- Hasegawa M, Nasuhara Y, Onodera al Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 20061731309–1315.
Source: PubMed